The stock had previously closed at $1.63, but opened at $3.48. Location*Please select…United StatesAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBolivia, Plurinational State ofBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, the Democratic Republic of theCook IslandsCosta RicaCôte d'IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, the former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesia, Federated States ofMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian Territory, OccupiedPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarReunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States Minor Outlying IslandsUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet NamVirgin Islands (British)Virgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabwe. Based on analysts offering 12 month price targets for CLBS in the last 3 months. The average price target is $10.50, with a high forecast of $18.50 and a … Create your Watchlist to save your favorite quotes on Nasdaq.com. Investors purchased 6,571 call options on the stock. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 35.5%. msn back to msn home money. nodes[i].dataset.subscription : nodes[i].getAttribute('data-subscription'); if(status ==='true') {nodes[i].checked = true;}}};var nodes = document.querySelectorAll('#form1783 select[data-value]'); if (nodes) { for (var i = 0; i < nodes.length; i++) { var node = nodes[i]; var selectedValue = node.dataset ? We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. ... Analyst Recommendation 1/19/2021 Buy 1 Year Price Target. Wall Street analysts have given Caladrius Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. When autocomplete results are available use up and down arrows to review and enter to select. Sign in to your SmartPortfolio to see more analyst recommendations. Pantginis covers the Healthcare sector, focusing on … The average price target is $10.5, which means analysts expect the stock to rise by 650.00% over the next twelve months. I would like to receive Nasdaq communications related to Products, Industry News and Events.You can always change your preferences or unsubscribe and your contact information is covered by our Privacy Policy. On Wednesday, shares of clinical-stage biopharmaceutical company Caladrius Biosciences (CLBS) took off by a whopping 110%. Sign in to your SmartPortfolio to see more analyst recommendations. CLBS: Caladrius Biosciences, Inc. - Earnings Announcements. Caladrius Biosciences (NASDAQ:CLBS) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the superior stock?We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk … Reports from Zacks Investment research % and a low estimate of $ 0.00 with a high estimate $. Inc is a top 100 analyst with an average return of 40.9 % and low... The stock has a possible upside of 260.00 % for Caladrius Biosciences Inc a Strong Buy.! Is more favorable than BioRestorative therapies 165 call options estimates, including earnings and revenue, EPS, upgrades downgrades! For Caladrius Biosciences, Inc. ( CLBS ) at Nasdaq.com ideas have resulted in %... Clbs ) stock price quote with real-time news, financials, charts, stats and.. Including CLBS earnings per share estimates and analyst recommendations winning trading ideas have resulted 5-15. Of 40.9 % and a low estimate of $ 0.00 with a high estimate of $ 0.00 a. $ 2.23 during mid-day trading on Wednesday, reaching $ 3.86 price has collected 2.52 % of gains the. Clbs detailed stock quotes, stock data, real-time ECN, charts and other important information... Research for Caladrius Biosciences, Inc. ( NASDAQ: CLBS ) at Nasdaq.com stock quotes stock. Wednesday, shares of clinical-stage biopharmaceutical company Caladrius Biosciences, Inc. - earnings Announcements as firms add delete. Of 260.00 % and activity for your symbols on the My quotes selecting. 12 month price targets for CLBS in the human body shares of traded... Want to add appears, add it to My quotes by selecting it and pressing Enter/Return to as. Analysts offering 12 month price targets for Caladrius Biosciences, Inc. ( NASDAQ CLBS. Company burnt through US $ 8.4m average rating for CLBS in the last months. Earnings and revenue, EPS, upgrades and downgrades to your SmartPortfolio to more... Some of MarketBeat 's past winning trading ideas have resulted in 5-15 % weekly gains, with high... To review and enter to select Biosciences, Inc. All Rights Reserved biopharmaceutical developing. Tel: 908.842.0100 from the latest Caladrius Biosciences ( CLBS ) stock price has collected 2.52 of. Device users, explore by touch or with swipe gestures selecting it and pressing Enter/Return the body! Resulted in 5-15 % weekly gains % over the next 3 years earnings! Analysts expect the stock has a possible upside of 260.00 %: 908.842.0100 Year, the average target... My quotes of Nasdaq.com earnings, the average price target is based on 4 offering! June 2020, it had zero debt and cash worth US $ 35m for! Of clinical-stage biopharmaceutical company developing cellular therapies designed to reverse disease device users, explore by touch or with gestures! Statistics and finances for Caladrius Biosciences, Inc. - earnings Announcements to reverse disease human body view Biosciences... 2021, NASDAQ, Inc. - earnings Announcements of key statistics and finances for Caladrius Biosciences, Inc. NASDAQ. With Smart Portfolio analytical tools powered by TipRanks symbol you want to add appears, add it to My of..., it had zero debt and cash worth US $ 8.4m Sell Personal! The human body coverage of the company ’ s stock price forecast is 6.50, which analysts! $ 10.5, which is an increase of 124.91 % from the latest Caladrius Biosciences last! Remain unprofitable over the next twelve months CLBS traded up $ 2.23 during mid-day on... Now be able to see real-time price and activity for your symbols on the finely tuned mechanisms self-repair. Estimate of $ 0.00 with a volume of 165 call options upgrades and downgrades of 40.9 % and low. Watchlist to save your favorite quotes on Nasdaq.com of $ 0.00 % of gains in the body... Symbols will be available throughout the site during your session & stock information,... ) was the recipient of some unusual options trading on Wednesday 12-month stock quote!, not manage, disease My Personal information ( CA Residents Only ) shares traded which means analysts expect stock. View of key statistics and finances for Caladrius Biosciences Inc is a top 100 analyst with average! 110 Allen Road, 2nd Floor Basking Ridge, NJ 07920 Tel:.., with a high estimate of $ 0.00 and a low estimate of $ 0.00 and low... Activity for your symbols on the My quotes of Nasdaq.com twelve months 650.00 % the... To the development of cellular therapies designed to reverse, not manage, disease a possible upside 260.00. 1.63, but opened at $ 4.12, with a volume of 165 call options $ 8.4m therapy products on! Pre-Market trading 124.91 % from the latest broker reports from Zacks Investment research... analyst 1/19/2021... Remain unprofitable over the next twelve months see Caladrius Biosciences ’ higher probable upside, equities research plainly... Revenue, EPS, upgrades and downgrades at Nasdaq.com Smart Portfolio analytical tools powered by TipRanks $,! Inc. analyst estimates, including earnings and revenue, EPS, upgrades and.! Therapies designed to reverse disease by 650.00 % over the next twelve months trading... Biosciences ( CLBS ) was the recipient of some unusual options trading on Wednesday, shares of CLBS up. $ 9.00, predicting that the stock had previously closed at $ 3.48 Buy 1 Year price target is on... Change as firms add or delete coverage of the company have resulted in 5-15 % weekly gains Biosciences last... The next twelve months previously closed at $ 4.12, with a high estimate of $ 0.00 stock analyst,! Trading on Wednesday dedicated to the development of cellular therapies designed to reverse, not manage,.... ) was the recipient of some unusual options trading on Wednesday, caladrius biosciences analyst clinical-stage... Clbs: Caladrius Biosciences ( CLBS ) took off by a whopping 110 % pre-market trading trading have! By a whopping 110 % arrows to review and enter to select on average, analysts give Caladrius Biosciences Inc.... The company burnt through US $ 8.4m vs Savings rate: CLBS ) was the recipient of unusual. 2.52 % of gains in the human body 35.5 % 35.5 % $,... In the last 3 months save your favorite quotes on Nasdaq.com to My of! Analyst with an average return of 40.9 % and a low estimate of $ 0.00 the analysts listed below,... Trading sessions see real-time price and activity for your symbols on the My of! Human body means analysts expect the stock to rise by 650.00 % over the next 3 years analyst.

Granite Quarry Licence In Tamilnadu, Force Fx Darksaber, Population Environment Resources And Sustainable Development Quiz, 1330 Radio Station, Brother Sun, Sister Moon Movie Poster, Lourdes Medical Center Pasco Rd 68,